Performance of Glass-ionomer Cements: 2-year Follow-up
Performance of Glass-ionomer Cements in the Pit and Fissure Sealing and Atraumatic Restorative Treatment: a Randomized 2-year Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Volunteers that having at least two permanent first molars of opposite sides of the mouth, erupted in the oral cavity, caries-free and high-risk disease (presence of white spots, history of caries, plaque in smooth surfaces and gingivitis);
- Children who had one or two bilateral matched pairs of carious deciduous molars that required either class I or class II restorations.
Exclusion Criteria:
- Children who did not meet the minimum requirements for the achievement of sealants or parents / guardians did not agree to participate;
- No history of spontaneous pulpal pain.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Ketac Molar® (3M/ESPE) - Glass ionomer
Pit and fissure sealing using conventional glass-ionomer cement
|
Application of preventive agent
|
|
Experimental: Maxxion® (FGM) - Glass ionomer cement
Pit and fissure sealing using conventional glass-ionomer cement
|
Application of preventive agent
|
|
Active Comparator: Ketac Molar® (3M/ESPE) - Glass ionomer -
Restoration using conventional glass-ionomer cement
|
Atraumatic Restorative Treatment
|
|
Experimental: Maxxion® (FGM) - Glass ionomer cement -
Restoration using conventional glass-ionomer cement
|
Atraumatic Restorative Treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of the teeth with glass-ionomer cement retention and prevention of caries.
Time Frame: 6-month
|
Criteria established by Frencken et al. (1998) was used.
|
6-month
|
|
Number of the teeth with good restoration and caries absence.
Time Frame: 6-month
|
Criteria established by Frencken et al. (1998) was used.
|
6-month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of loss of the sealing material and prevention of caries.
Time Frame: 6-month
|
Criteria established by Frencken et al. (1998) was used.
|
6-month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Raquel V Rodrigues, PhD Student, Piracicaba Dental School - University of Campinas
- Principal Investigator: Ana Carolina G Luciano, DDS, Piracicaba Dental School - University of Campinas
- Principal Investigator: Kelly MS Moreira, MS Student, Piracicaba Dental School - University of Campinas
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Stomatognathic Diseases
- Tooth Demineralization
- Tooth Diseases
- Dental Caries
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
Other Study ID Numbers
Other Study ID Numbers
- 3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.